Drug Database
Back to search

France· FR:69240179

KEVZARA 200 mg, solution injectable en seringue préremplie

A sarilumab product containing sarilumab, registered in France by SANOFI WINTHROP INDUSTRIE, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L04AC14

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedKEVZARA 200 mg, solution injectable e…ATCL04AC14REGISTER NO.FR:69240179PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sarilumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Sarilumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AC14 (sarilumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose
Search sarilumab products by name

Sarilumab · ATC L04AC14

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sarilumab costs, country by country.

Normalised to the WHO defined daily dose (14.3 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Sarilumab · price per daily dose (14.3 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$60.91
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
SARILUMAB
Manufacturer
SANOFI WINTHROP INDUSTRIE
Country
France (FR)
ATC code
L04AC14
ATC class
Sarilumab
Defined daily dose
14.3 mg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930100615
    2 seringue(s) préremplie(s) en verre à usage unique de 1,14 ml
    EUR 669.86

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

190 interactions on record for sarilumab.

Graded by severity as the source publishes them — 39 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check sarilumab against other medicinesHow interaction checks work

Sarilumab · interactions on record

190 records

  • 39 severe
  • 144 moderate
  • 7 minor

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • CladribineL01BB04severe
  • PexidartinibL01EX15severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Sarilumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sarilumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Kevzara
  • Liechtenstein · Kevzara
  • Norway · Kevzara

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ebd724e4-ef96-4966-aa99-627633c9b569
GET /v1/drugs/ebd724e4-ef96-4966-aa99-627633c9b569?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69240179",
  "date_amm": "2017-06-23",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/17/1196",
  "substance": "SARILUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about sarilumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console